Showing real-world impact through policy documents and clinical guidelines citations
At BMJ Group, we focus on making a real-world impact through our publications. While scholarly influence is significant, we can see its value in real-world implications for policy and clinical guidelines and how it drives health and social care change.
According to credible data provided by BMJ Impact Analytics, in 2023, research papers published by BMJ Group were cited in over 7000 policy documents and clinical guidelines, directly improving clinical practice and how health and social care is provided.
This places us among the top ten most influential publishers on health and social care policy, outperforming many larger publishers in terms of our real-world impact.
It also illustrates our ability to deliver the best available research that resonates deeply with the clinical community.
Accelerating research insights into clinical practice and policy guidelines
Inspiring real change through global reach and recognition
Typically, research takes five to 15 years to impact clinical guidelines. Various factors influence this timeline, from the quality and strength of evidence to peer review, publication, design development processes, consensus, and clinical adoption. BMJ Group’s brand recognition and global reach can accelerate this process by improving clinical practice worldwide.
The international readership spanning BMJ Group’s 60+ journal collection ensures that the impact of the articles we publish extends beyond national borders, influencing healthcare practices and policies in numerous countries.
In October 2020, an observational study published in the Journal of Neurology, Neurosurgery & Psychiatry compared outcomes after treatment with autologous haematopoietic stem cell transplantation (AHSCT) and alemtuzumab (ALZ) in patients with relapsing-remitting multiple sclerosis.
In less than four years, the research paper was cited in clinical guidelines in three countries, Canada, Germany, and the Netherlands, with references from four different sources. It also helped lower-income countries provide affordable care for people living with multiple sclerosis, offering clear treatment outcomes that shaped guideline amendments and impacted care practices globally.
My research is particularly aimed at professionals working in low-income healthcare systems, so it has to be open access to reach them.”
Joachim Burman, “
Consultant Neurologist and Associate Professor of Neurology in Sweden
